- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04417309
Can Exercise Improve Therapeutic Learning Among Women With Posttraumatic Stress Disorder (PTSD)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40505
- University of Kentucky
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Current diagnosis of PTSD where the index traumatic event includes physical or sexual assault
- English speaking
- Medically healthy
Exclusion Criteria:
- Any endorsed medical concerns related to physical activity (as probed in the phone screening questions regarding cardiovascular, pulmonary, or metabolic disease and as assessed via the Physical Activity Readiness Questionnaire (PAR-Q), which probes into participants' history of heart conditions, chest pain, dizziness, loss of consciousness, bone/joint problems, and medication history). Participants would not be excluded if they report this condition being "controlled" or "addressed" through medication or lifestyle change, such as regular exercise.
- Major medical disorders (such as cancer, AIDS)
- Physical discomfort or difficulty with blood draws
- Psychotic disorders
- Intellectual disabilities
- Developmental disorders
- Active substance use disorders
- Pregnancy
- Due to safety concerns, participants with these conditions will be ineligible to participate:
- Major medical disorders (e.g., HIV, cancer)
- Daily cannabis use
- History of light headedness or fainting during blood draws or physical activity
- History of chest pain during physical activity
- Abnormal EKG finding at intake visit screening, without follow-up clearance from their physician
- Bone, joint, cardiac, pulmonary, metabolic, or other medical conditions that may be worsened by physical activity (e.g., Chronic Obstructive Pulmonary Disease (COPD), diabetes, hypertension) that is not currently addressed via medication or lifestyle change.
- A positive pregnancy test
- A self-reported history of loss of consciousness (greater than 30 minutes)
- Physical disabilities that prohibit task performance (such as blindness or deafness)
- Psychotic disorders (e.g., schizophrenia)
- Any other condition that the investigator believes might put the participant at risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Moderate Intensity Exercise
Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by moderate intensity exercise), Day 4 Recall of Fear Extinction Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction |
Behavioral: Moderate Intensity Exercise The moderate-intensity aerobic exercise session will consist of walking or running at a moderate intensity (i.e., between 70-75% MHR) for 30 minutes.
|
Active Comparator: Control
Day 1 Assessment, Day 2 Fear Learning, Day 3 Fear Extinction (followed by low intensity exercise), Day 4 Recall of Fear Extinction Other: Day 1 Assessments Other: Day 2 Fear Learning Other: Day 3 Fear Extinction Behavioral: Moderate Intensity Exercise Other: Day 4 Recall of Fear Extinction |
Behavioral: Low Intensity Exercise Control participants will maintain light-intensity activity (i.e., walking at ~50% of MHR) for 30 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Skin Conductance Responding (SCR)
Time Frame: up to Day 4
|
Aim 1 fear extinction analyses consists of a 2 (group: low-intensity exercise vs moderate-intensity exercise) x 2 (cue: conditioned fear and safety) x 2 (task phase context: learning context vs extinction context) mixed design focused on Day 4 fear responding (skin conductance responses).
SCR data will be acquired on a BIOPAC MP150 Data Acquisition System (BIOPAC Systems, Inc.) with electrodes placed on participant's left hand.
Participants will be instructed to select an intensity of a 7/10 on the subjective pain scale, which should be "uncomfortable, but not painful."
Average intensity of participant skin conductance will be reported.
|
up to Day 4
|
Participant Expectancy Ratings
Time Frame: Up to day 4
|
Aim 1 fear extinction analyses consists of a 2 (group: low-intensity exercise vs moderate-intensity exercise) x 2 (cue: conditioned fear and safety) x 2 (task phase context: learning context vs extinction context) mixed design focused on Day 4 fear responding (expectancy ratings).
Expectancy will be assessed throughout each phase of the experiment to estimate the degree to which the subject believes she will receive a shock following presentation of certain pictures presented during the experiment.
|
Up to day 4
|
Group Differences in Serum Brain-Derived Neurotrophic Factor (BDNF)
Time Frame: before and after 30 min exercise on Day 3
|
Aim 2 group differences in BDNF consists of a 2 (group: moderate-intensity vs low-intensity) x 2 (cue: conditioned fear and safety) x 2 (task phase context: learning context vs extinction context) x 2 (timepoint: pre condition vs post condition,) mixed design.
The hypothesis is BDNF increases following exercise will separately mediate the relationship between aerobic exercise and enhanced fear extinction recall.
|
before and after 30 min exercise on Day 3
|
Group Differences in Serum Endocannabinoid (eCB) Content
Time Frame: before and after 30 min exercise on Day 3
|
Aim 2 group differences in eCB consists of a 2 (group: moderate-intensity vs low-intensity) x 2 (cue: conditioned fear and safety) x 2 (task phase context: learning context vs extinction context) x 2 (timepoint: pre condition vs post condition,) mixed design.
The hypothesis is eCBs increases following exercise will separately mediate the relationship between aerobic exercise and enhanced fear extinction recall.
|
before and after 30 min exercise on Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Profile of Mood States (POMS) Questionnaire
Time Frame: at each visit, up to Day 4
|
The POMS survey is a 65-item survey scored on a 5 point Likert Scale (0-4) where 0 s 'not at all' and 4 is 'extremely' for the tension, depression, fatigue, confusion, and anger subscales, and reversed for the vigor and esteem-related affect subscales.
The range of total possible scores is XX-XX with higher numbers indicating more extreme or negative moods.
|
at each visit, up to Day 4
|
Change in State-Trait Anxiety Inventory (STAI)
Time Frame: at each visit, up to Day 4
|
STAI is a 20-item assessment rated on a 4-point scale from 'almost never' to 'almost always' with the total scores ranging from 20-80.
Higher scores indicate greater anxiety.
|
at each visit, up to Day 4
|
Change in Positive and Negative Affect Scale (PANAS)
Time Frame: at each visit, up to Day 4
|
PANAS is comprised of two 10-item scales for both positive and negative affect.
Total combine scoring is from 20-100 where the higher the score the more negative the affect.
|
at each visit, up to Day 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Thomas G Adams Jr, PhD, University of Kentucky
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 58938
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Recruiting
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on Experimental
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHPV | Related Malignancy | Related CarcinomaUnited States
-
Finis Terrae UniversityNot yet recruitingPostoperative Pain | Respiratory ComplicationChile
-
Wake Forest University Health SciencesMichael J. Fox Foundation for Parkinson's ResearchWithdrawn
-
Piedmont HealthcareLivaNovaCompletedHeart FailureUnited States
-
University of Illinois at ChicagoRecruiting
-
Polish Mother Memorial Hospital Research InstituteCompletedBottle Feeding | PrematurePoland
-
Le Mans UniversiteNot yet recruiting
-
Aston UniversityBirmingham Women's and Children's NHS Foundation TrustRecruitingReflex Epilepsy, Photosensitive | EyeglassesUnited Kingdom
-
Cardenal Herrera UniversityNot yet recruiting
-
Assistance Publique - Hôpitaux de ParisMedtronic - MITG; Kimberly-Clark CorporationCompletedMechanical Ventilation Complication | Acute Respiratory FailureFrance